Global Leading Market Research Publisher QYResearch announces the release of its latest report “Surgical Use Plant based Hemostat Powder – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. This report provides a comprehensive analysis of the global surgical use plant-based hemostat powder market, directly addressing the critical bleeding control challenges facing surgeons in operating rooms: managing diffuse bleeding (oozing from parenchymal organs, bone surfaces, and soft tissues) where traditional clamping or cautery is ineffective, reducing operative time and blood loss, and minimizing the risk of post-operative complications (hematoma, re-operation for bleeding). For hospital procurement managers, surgical services directors, and medical device investors, understanding market share distribution across product sizes (1g, 3g, 5g), comparative advantages over animal-derived hemostats, and adoption drivers in public vs. private hospitals is essential for formulary inclusion and strategic sourcing decisions.
Surgical use plant-based hemostat powder is a topical hemostatic agent derived from plant sources (typically purified potato starch, corn starch, or other botanical polysaccharides) that accelerates blood clotting when applied to bleeding surgical sites. The mechanism involves particle aggregation at the bleeding site, concentrating platelets and coagulation factors, and forming a mechanical barrier. Plant-based hemostats are typically absorbable (biodegraded by amylase within 24-48 hours) and do not induce the foreign body reactions sometimes associated with animal-derived products (collagen, gelatin, thrombin from bovine or porcine sources). The conventional hemostat powder market has long relied on animal-derived products, raising concerns about sustainability and potential allergic reactions. In contrast, plant-based hemostat powder offers a safe, effective, and environmentally conscious solution, with advantages including no risk of prion transmission (bovine spongiform encephalopathy – BSE), no religious or cultural restrictions (kosher, halal, vegetarian/vegan compatibility), lower immunogenicity, and consistent supply unaffected by animal disease outbreaks.
According to QYResearch’s proprietary data, the global surgical use plant-based hemostat powder market was valued at approximately US280millionin2025andisprojectedtoreachUS280millionin2025andisprojectedtoreachUS 490 million by 2032, growing at a strong CAGR of 8.3% during the forecast period 2026-2032. North America currently holds the largest market share (approximately 38-40%), driven by high surgical volumes (estimated 50-60 million surgical procedures annually in the US), strong adoption of advanced hemostatic products, and increasing preference for non-animal-derived surgical materials. Europe follows (30-32%), with Asia-Pacific (18-20%) emerging as the fastest-growing region (projected 10.5% CAGR), driven by expanding surgical capacity in China and India and growing awareness of plant-based alternatives.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5972520/surgical-use-plant-based-hemostat-powder
1. Product Type Segmentation: 1g, 3g, 5g, and Others
The market research landscape for surgical use plant-based hemostat powder is defined by package size, which corresponds to anticipated bleeding severity and surgical application. Four primary size categories dominate:
- 3g (40-45% of 2025 revenue): The largest segment, representing the most commonly used size for moderate bleeding in general surgical procedures (laparotomy, colectomy, cholecystectomy, hysterectomy). Sufficient for application to 50-100 cm² of bleeding surface. Average pricing US$ 60-120 per unit (depending on brand and contract terms).
- 1g (30-35%): Used for minor bleeding in laparoscopic procedures (where smaller application is required), neurosurgery (precise application around neural structures), and cardiovascular surgery (small oozing sites). Average pricing US$ 25-50 per unit. This segment is growing faster (9.5% CAGR) as minimally invasive surgery volumes increase.
- 5g (15-20%): Used for major bleeding in trauma surgery, liver transplantation (raw liver surface after resection), orthopedic surgery (large bone surfaces), and burn debridement. Average pricing US$ 100-200 per unit.
- Others (3-5%): Includes 10g sizes for specialized applications and multi-pack configurations.
A key technical development in 2025 is the introduction of powder application devices that facilitate precise, dust-free delivery of plant-based hemostat powder. Traditional powder application involves opening the pouch and pouring or using a syringe; newer devices (e.g., PlantTec Medical GmbH’s “HydroSpray” system) use CO₂-powered or manual bellows for targeted, even distribution, reducing powder waste by 40-60% and improving visualization at the surgical site. These devices are typically sold separately or as combination kits with the powder.
2. Application Segmentation: Public Hospital, Private Hospital, and Others
- Public Hospital (60-65% of 2025 revenue): The dominant application segment, encompassing government-funded and non-profit hospitals that perform the majority of surgical procedures globally (particularly in universal healthcare systems: UK’s NHS, Canada’s Medicare, Germany’s statutory health insurance). Public hospitals are typically more price-sensitive, driving demand for cost-effective plant-based hemostats. Group purchasing organizations (GPOs) in the US and national tenders in Europe negotiate pricing, with contract prices often 15-25% below list prices. A representative case: The UK NHS awarded a 3-year national framework agreement for hemostatic products in Q4 2025, including plant-based hemostat powder. The contract stipulated minimum 70% plant-based sourcing (vs. animal-derived) to meet NHS sustainability targets (Net Zero by 2040). The successful bidder offered plant-based powder at £25-45 per 3g unit, substantially lower than animal-derived alternatives (£60-100).
- Private Hospital (30-35%): Private, for-profit hospitals (US, Latin America, Middle East, Asia-Pacific). Private hospitals are less price-sensitive and more willing to adopt premium plant-based products, emphasizing faster operating room turnover, reduced re-operation rates, and patient satisfaction (including avoidance of animal-derived products for religious or dietary reasons). Private hospitals also have higher adoption of advanced delivery devices.
- Others (3-5%): Ambulatory surgical centers (ASCs), military field hospitals, veterinary surgery.
3. Competitive Landscape: Global Market Share Analysis
The surgical use plant-based hemostat powder market is moderately concentrated, with major surgical device companies and specialized biomaterial providers. Key players and estimated market share positions include:
- Ethicon (Johnson & Johnson, USA): Holds approximately 18-22% market share, the global leader with SURGICEL® (oxidized regenerated cellulose) and ETHICON hemostat powder portfolio. While Ethicon’s classic products are plant-derived (cellulose-based), they have faced increased competition from newer starch-based powders with different handling characteristics. Ethicon’s 2025 hemostat revenue exceeded US$ 800 million globally across all product forms.
- Baxter (USA): Commands approximately 14-17% market share, with FLOSEAL® (gelatin + thrombin, animal-derived) but also COSEAL® (polyethylene glycol-based synthetic; plant-avoiding but not plant-derived). Baxter has invested in plant-based R&D and is expected to launch a starch-based powder by 2026-2027.
- BD (Becton Dickinson, USA): Holds approximately 8-10% market share, with surgical hemostat products including plant-based offerings.
- Biocer (France): Accounts for approximately 5-7% market share, a European specialty company with plant-derived hemostat powder products (starch-based), strong in EU public hospital tenders.
- Hemostasis (USA): Holds approximately 4-6% market share, focusing exclusively on plant-based hemostat powder (rice starch-based). Their “PlantAct” product line differentiates on allergen-free processing (no gluten, no soy, no nuts) and kosher/halal certification.
- PlantTec Medical GmbH (Germany): Commands approximately 3-5% market share, a fast-growing European startup offering starch-based powder with proprietary delivery device (HydroSpray). Focus on private hospitals and premium positioning.
- Starch Medical (USA): Holds approximately 2-4% market share, specialized in potato starch-based hemostat powder with patented particle sizing for optimal handling.
Other notable players include Theracion Biomedical (South Korea), Singleclean (China, domestic plant-based hemostat manufacturer), and smaller regional suppliers.
4. Unique Industry Observation: Animal-Derived vs. Plant-Based Substitution Dynamics
A distinctive industry dynamic rarely highlighted in standard market reports is the substitution dynamics between animal-derived hemostats (gelatin, collagen, thrombin from bovine/porcine sources) and plant-based hemostats (starch, cellulose). This is not a simple “performance” substitution but a complex, multi-factor decision.
Animal-derived hemostats advantages: longer clinical track record (decades of use), broader range of product formats (powder, sheet, sponge, gel), and established surgeon familiarity. Disadvantages: religious/cultural restrictions (porcine-derived products not acceptable in Jewish/Muslim communities; bovine-derived issues for some Hindu patients), potential for prion transmission (BSE theoretical risk; actual transmission never documented for hemostats), sustainability concerns (animal agriculture environmental footprint), and bovine thrombin-associated antibody formation (rare but documented coagulopathy).
Plant-based hemostats advantages: universal acceptance across religious/cultural groups, lower immunogenicity, consistent supply (not dependent on animal slaughter cycles), and favorable environmental profile. Disadvantages: newer to market (limited long-term data for some products), different handling characteristics (may require different application technique), and for some products, less effective on heavy bleeding (most plant-based powders are indicated for mild-to-moderate oozing, not arterial bleeding).
This operational distinction directly informs hospital formulary strategy:
- Hospitals with diverse patient populations (religious/cultural sensitivity): Plant-based hemostats should be preferred for all patients to avoid need for product substitution based on patient preference.
- High-volume trauma centers: Both product types needed; plant-based for moderate oozing, animal-derived or synthetic for more severe bleeding.
- Sustainability-focused hospitals (NHS, Kaiser Permanente): Plant-based hemostats align with net-zero procurement commitments.
5. Market Outlook and Strategic Recommendations for 2026-2032
By 2032, the global surgical use plant-based hemostat powder market size is expected to reach US$ 490 million, growing at an 8.3% CAGR. The 3g size will maintain market share leadership (42-45%), with 1g growing fastest (9.5% CAGR) driven by laparoscopic and minimally invasive surgery expansion. However, three challenges and opportunities shape the outlook:
- Clinical evidence generation: Plant-based hemostats require comparative studies vs. animal-derived products to support surgeon adoption and hospital formulary inclusion. Published RCTs are limited; more Level 1 evidence needed.
- Reimbursement and coding: In the US, hemostat powder is billed under supply codes with reimbursement varying by setting. Private hospitals may have better reimbursement than public.
- Competition from synthetic and advanced hemostats: PEG-based synthetic products (COSEAL, DURASEAL) offer different mechanisms and compete in similar applications.
For hospital procurement managers and surgical services directors, this market research suggests:
- Public hospitals with sustainability mandates: Prioritize plant-based hemostats for mild-to-moderate bleeding; ensure pricing competitive with animal-derived products
- Private hospitals with diverse patient populations: Plant-based preferred for all patients to simplify inventory and avoid religious/cultural objections
- Clinical preference considerations: Engage surgeons in product evaluation; handling characteristics vary between plant-based and animal-derived products (powder consistency, application ease, adhesion)
The complete report, including Full TOC, 30 data tables, 26 figures, and detailed competitive benchmarking across 10 manufacturers, is available via the sample PDF link above.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
